Item no. |
CS-CRI225C |
Manufacturer |
Cell Sciences
|
Amount |
1.0 mg |
Category |
|
Type |
Proteins |
Specific against |
Human (Homo sapiens) |
Host |
E.coli |
Purity |
>97.0% by HPLC and SDS-PAGE |
Sequence |
MSITGISPIT EYLASLSTYN DQSITFALED ESYEIYVEDL KKDEKKDKVL LSYYESQHPS NESGDGVDGK MLMVTLSPTK DFWLHANNKE HSVELHKCEK PLPDQAFFVL HNMHSNCVSF ECKTDPGVFI GVKDNHLALI KVDSSENLCT ENILFKLSET |
ECLASS 10.1 |
32160409 |
ECLASS 11.0 |
32160409 |
UNSPSC |
12352202 |
Similar products |
IL-33, C9orf26, DKFZp586H0523, DVS27, NF-HEV, NFEHEV, RP11-575C20.2, DVS27-related protein, nuclear factor from high endothelial venules, IL-1F11, interleukin-33, interleukin-1 family member 11 |
Available |
|
Biological Activity |
Fully biologically active when compared to standard. The ED50 determined by a cell proliferation assay using mouse 10S cells is less than 0.05 ng/ml. |
Description |
IL-33, encoded by IL-33 gene located on the Chr.9 in humans, is a 30 kDa proinflammatory protein belonging to the IL-1 superfamily and it shares less than 20% a.a. sequence identity with other members. IL-33 secreted by high endothelial venules at high levels, which is found in tonsils, peyer patches and mesenteric lymph nodes, but not in placenta. It is upregulated in arterial smooth muscle, dermal fibroblasts, and keratinocytes following IL-1 alpha or IL-1 beta stimulation. It elicits its biological effects by interacting with IL1RL1/ST2 and its stimulation recruits MYD88, IRAK1, IRAK4, and TRAF6, followed by phosphorylation of MAPK3/ERK1 and/or MAPK1/ERK2, MAPK14, and MAPK8. IL-33 mature protein has 52-58% a.a. sequence identity with mouse and rat IL-33. Recombinant Human Interleukin-33 is a single non-glycosylated polypeptide chain containing 160 amino acids. |
Endotoxin Level |
<1 EU/ug as determined by LAL method. |
Formulation |
Lyophilized from a 0.2 um filtered concentrated solution in 20 mM PB + 150 mM NaCl + 1 mM EDTA + 2 mM a-Mercaptoethanol, pH 7.4 |
Molecular Weight |
17.9 kDa |
Reconstitution |
Centrifuge vial prior to opening. Add sterile distilled water or aqueous buffer to a concentration of 0.1-1.0 mg/ml. Further dilutions should be made in appropriate buffered solutions. |
Storage and Stability |
This lyophilized preparation is stable at 2-8C. Upon receipt, store desiccated at -20C. After reconstitution, the preparation is stable for up to one week at 2-8C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20C to -80C. For long term storage of reconstituted protein, it is recommended that a carrier protein such as 0.1% BSA or HSA be added. This depends on the particular application. Avoid repeated freeze/thaw cycles. |
Specificity |
>2.0 x 10E7 IU/mg. |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.